Closing Bell Movers: Deckers falls 15% on weak guidance; Nuclear names rally

In the opening hour of the evening session, U.S. equity futures are down marginally – S&P 500 is off by 0.1% at 5,852, Nasdaq 100 is off by 0.2% below 21,150, and Dow Industrials are off by a fraction just above 41,900.  In commodities, global growth concerns have further pressured energy, with WTI Crude slipping below $61 per barrel, while Gold is little changed just below $3,300 level.

Among key afterhours earnings, Intuit was a bright spot, with a Q3 beat on top and bottom lines – along with better than expected Q4 guidance – sending the stock to 2025 highs above $700.  Discretionary retail saw fresh evidence of tariff-related uncertainty as both Deckers and Ross Stores offered weaker than expected guidance after better than expected results while deferring on longer-term outlook, sending shares of both names lower.  Elsewhere, uranium/nuclear stocks rallied following a Reuters report that President Trump is preparing to sign executive orders tomorrow streamlining the use of nuclear power.

Check out this evening’s top movers from around Wall Street, compiled by The Fly.

HIGHER AFTER EARNINGS –

• NANO Nuclear Energy Inc. (NNE) up 12.3%
• StepStone Group Inc. (STEP) up 9.7%
• Intuit (INTU) up 7.9%
• Autodesk (ADSK) up 3.2%

ALSO HIGHER –

• Merus N.V. (MRUS) up 20.9% after Petosemtamab+Pembrolizumab data
• Uranium Energy (UEC) up 8.7%, Oklo (OKLO) up 12.2%, NuScale Power (SMR) up 9.8%, Energy Fuels (UUUU) up 13.3%, ASP Isotopes Inc. (ASPI) up 12.8% after Reuters report that Trump will sign executive order boosting nuclear power use on Friday

DOWN AFTER EARNINGS –

• Deckers Outdoor (DECK) down 15.5%
• Ross Stores (ROST) down 11.0%
• Workday (WDAY) down 6.4%
• Webull Corporation (BULL) down 5.6%

ALSO LOWER –

• Bicara Therapeutics (BCAX) down 23.1% after publication of abstract with updated interim data from Phase 1/1b Trial of Ficerafusp
• Hallador Energy (HNRG) down 16.9% after disclosing loss of contract with datacenter developer
• Gyre Therapeutics (GYRE) down 15.3% after equity offering